PPARα or PPARγ agonists increase the levels of adiponectin, such as some treatments for cardiovascular diseases like angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, or rosiglitazone in type 2 diabetes and statins in hypercholesterolemic patients [132, 133]. This evidence concerns the gene ADIPOQ and cardiovascular disorder.